Novartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase & Co. Analysts

Novartis (VTX:NOVN) has been given a CHF 84 price target by stock analysts at JPMorgan Chase & Co. in a research report issued on Thursday, January 4th. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective would indicate a potential upside of 0.14% from the company’s current price.

Several other research firms have also commented on NOVN. UBS Group set a CHF 78 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Monday, October 23rd. Morgan Stanley set a CHF 88 price target on shares of Novartis and gave the company a “buy” rating in a research report on Friday, October 20th. Deutsche Bank set a CHF 83.50 price objective on shares of Novartis and gave the company a “neutral” rating in a research note on Wednesday, October 4th. S&P Global set a CHF 87 price objective on shares of Novartis and gave the company a “neutral” rating in a research note on Tuesday, October 24th. Finally, set a CHF 90 price objective on shares of Novartis and gave the company a “buy” rating in a research note on Monday, October 30th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 86.97.

Shares of Novartis (VTX NOVN) opened at CHF 83.88 on Thursday. Novartis has a one year low of CHF 69.50 and a one year high of CHF 85.40. The company has a market cap of $218,960.00 and a P/E ratio of 30.61.

ILLEGAL ACTIVITY NOTICE: “Novartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase & Co. Analysts” was published by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/jpmorgan-chase-co-analysts-give-novartis-novn-a-chf-84-price-target/1804160.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.